default author photo

Seema U. Nayak

Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID)

Bethesda, MD 20814

United States

SCHOLARLY PAPERS

2

DOWNLOADS

253

TOTAL CITATIONS

4

Scholarly Papers (2)

1.

Effects of Jak Inhibitors in Adults Hospitalized Due to Covid-19: A Systematic Review and Individual Participant Data Meta-Analysis of Randomized Clinical Trials

Number of pages: 27 Posted: 03 Oct 2024
Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, University of Basel, University of Basel - University Hospital Basel, Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, Basel University - CLEAR Methods Center, University Hospitals of Geneva, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), The Emmes Company, Hospital Universitario de Fuenlabrada, Hospital Universitario de Fuenlabrada, Ospedali Riuniti di Ancona, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Mazandaran University of Medical Sciences, University of Cambridge, NHS Foundation Trust - Cambridge University Hospitals, Hospital Universitario La Paz, Hospital Universitario La Paz, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, Hospital Israelita Albert Einstein, Hospital Israelita Albert Einstein, University of Sydney - George Institute for Global Health, Hôpital Bichat - Claude-Bernard - INSERM, IAME Infectious Diseases Department, Norwegian Institute of Public Health, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Université Libre de Bruxelles (ULB) - Department of Infectious Disease, Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, University of Verona - Infectious Diseases, Department of Diagnostic and Public Health, Hôpital Bichat, APHP, Université Paris Cité, Université Paris Cité, Université Paris Cité, University of Nantes - INSERM, Sorbonne University, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Section for Clinical Immunology and Infectious Diseases and University of Basel - University Hospital Basel
Downloads 175 (437,795)

Abstract:

Loading...

2.

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant

Number of pages: 57 Posted: 08 Apr 2022
- Center for Vaccine Development and Global Health, Baylor College of Medicine, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, affiliation not provided to SSRN, - School of Medicine, Duke University - Duke Human Vaccine Institute, Kaiser Permanente Washington Health Research Institute, University of Rochester - Division of Infectious Diseases, Baylor College of Medicine, Emory University School of Medicine and Children’s Healthcare of Atlanta - Department of Pediatrics, University of Pittsburgh - School of Medicine, University of Washington, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, New York University (NYU) - Grossman School of Medicine, University of Cincinnati - College of Medicine, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, New York University (NYU) - New York University Long Island School of Medicine, New York University (NYU) - Grossman School of Medicine, affiliation not provided to SSRN, University of Pittsburgh - School of Medicine, Emory University - School of Medicine, affiliation not provided to SSRN, Seattle Children’s Research Institute, affiliation not provided to SSRN, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), affiliation not provided to SSRN, University of Washington - Vaccine and Infectious Disease Division, - Center for Vaccine Development and Global Health, affiliation not provided to SSRN, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Emory University - Center for Childhood Infections and Vaccines, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Duke University - Duke Human Vaccine Institute and affiliation not provided to SSRN
Downloads 78 (830,555)
Citation 4

Abstract:

Loading...

COVID-19, SARS-CoV-2, Booster, Vaccine, Omicron variant, B.1.1.529, Neutralizing antibody, mRNA vaccine, recombinant adenovirus vaccine